{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.88 vs. cons $1.84",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Core/Organic Revenue Growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~2.4% vs. cons 2.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Operating Margin (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~26.9% vs. cons 26.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.45-$8.65 vs. cons $8.46 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Core Revenue Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~3%-6% (reaffirmed, midpoint 4.5%) vs. cons 4.3% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 Core Revenue Growth / Margin Cadence Commentary",
      "prediction": "BETTER",
      "answer": "guide ~mid-single-digit core growth (~4%) vs. cons ~3% (Q3 2026), with margin recovering toward ~28% from Q2's 26.5%",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.2,
  "day5_path": "STABILIZE",
  "day5_rationale": "A modest EPS/margin/core-growth beat plus reaffirmed-to-slightly-raised FY guidance (now incorporating Masimo) should produce a positive but not explosive day-1 pop, since the stock already rallied ~24% off May lows and much of the bioprocessing-recovery/Masimo-optimism is pre-priced after Agilent's and ICON's strong prints. Out-period math is a wash: while Q2 margin dip was pre-guided (no incremental cut), Masimo integration costs, incremental amortization (~$1.7B FY26), higher interest expense, and lingering China VBP/Cepheid respiratory drag temper analysts' out-quarter EPS raises even if headline adjusted EPS beats \u2014 capping upward revisions. Conversely, continued bioprocessing equipment-order momentum and confirmation that H1 headwinds are fading on schedule should prevent the kind of macro-driven post-print selloff seen after Q1 (when the stock fell ~9% despite a beat-and-raise). Net effect: gains from the print largely hold over the week rather than compounding meaningfully higher or reversing \u2014 a stabilization pattern.",
  "day5_confidence": "LOW"
}